We are live on ! Find out more
FCM

Farallon Capital Management Portfolio holdings

AUM $17.5B
1-Year Est. Return 50.95%
This Fund
S&P 500
This Quarter Est. Return
+19.41%
1 Year Est. Return
+50.95%
3 Year Est. Return
+148.38%
5 Year Est. Return
+206.05%
10 Year Est. Return
+1,475.31%
AUM
$16.6B
AUM Growth
+$2.17B
Cap. Flow
-$81M
Cap. Flow %
-0.49%
Top 10 Hldgs %
31.47%
Holding
166
New
39
Increased
28
Reduced
33
Closed
30

Top Buys

Rank Stock Value
1
ARMK icon
Aramark
ARMK
+$366M
2
XLNX
Xilinx Inc
XLNX
+$332M
3
RTX icon
RTX Corp
RTX
+$299M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$289M
5
AVGO icon
Broadcom
AVGO
+$243M

Sector Composition

Rank Sector Weight
1 Healthcare 38.27%
2 Communication Services 13.23%
3 Financials 10.05%
4 Technology 9.85%
5 Industrials 8.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ARYBU
151
DELISTED
ARYA Sciences Acquisition Corp II Unit
ARYBU
-402,523
Closed -$4.43M
IMMU
152
DELISTED
Immunomedics Inc
IMMU
-5,860,000
Closed -$498M
HZNP
153
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
-150,000
Closed -$11.7M

Similar funds

Farallon Capital Management's Q4 2020 Portfolio in Review

As of Q4 2020, Farallon Capital Management held 166 positions worth $16.6B, up 15% from $14.5B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Farallon Capital Management's Q4 2020 filing shows 39 new, 28 increased, 33 reduced and 30 closed positions. Its largest new stake was Aramark: 15,268,169 shares worth $424M. The largest sale was Immunomedics Inc, an estimated $498M.

By sector, the portfolio is most concentrated in Healthcare at 38% of assets, down from 41% a quarter earlier, followed by Communication Services and Financials.

  • Farallon Capital Management's largest Q4 2020 buy was Aramark: 15,268,169 shares worth $424M.
  • Farallon Capital Management added most to Willis Towers Watson in Q4 2020, an estimated $188M increase.
  • Farallon Capital Management's biggest Q4 2020 reduction was AbbVie, cutting an estimated $298M.
  • Farallon Capital Management fully exited Immunomedics Inc in Q4 2020, selling an estimated $498M.
  • Farallon Capital Management's ten largest holdings make up 31% of its $16.6B portfolio in Q4 2020.
  • Farallon Capital Management opened 39 new positions and closed 30 in Q4 2020.
  • Farallon Capital Management's portfolio value rose 15% quarter-over-quarter to $16.6B.

Based on Farallon Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.